SHP 627

Drug Profile

SHP 627

Alternative Names: FT 001; FT-011; SHP627

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Fibrotech Therapeutics; University of Melbourne
  • Developer Shire
  • Class Anthranilic acids; Antifibrotics; Caffeic acids; Small molecules
  • Mechanism of Action Collagen inhibitors; Platelet-derived growth factor inhibitors; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic nephropathies; Focal segmental glomerulosclerosis
  • No development reported Heart failure; Kidney disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Australia (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Kidney-disorders in Australia (PO)
  • 02 May 2014 Fibrotech Therapeutics has been acquired by Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top